Loading the section…

ARQT: financial statements from SEC — TradeAlmanac

ARQT

Arcutis Biotherapeutics, Inc.: financial statements

Company reports as filed with the U.S. Securities and Exchange Commission.

AnnualQuarterly

Income statement

Metric	31/03/2026	30/09/2025	30/06/2025	31/03/2025	30/09/2024	30/06/2024
Revenue	105M	99M	82M	66M	45M	31M
Cost of revenue	10M	9M	7M	9M	6M	3M
Research and development	31M	20M	19M	18M	20M	19M
Selling, general and administrative	74M	62M	69M	64M	59M	58M
Operating expenses	114M	91M	96M	90M	84M	81M
Operating income	−9M	9M	−15M	−25M	−39M	−50M
Income tax	93,000	80,000	342,000	279,000	0	0
Net income	−11M	7M	−16M	−25M	−42M	−52M
Earnings per share	−0.09	0.06	−0.13	−0.20	−0.33	−0.42
Earnings per share, diluted	−0.09	0.06	−0.13	−0.20	−0.33	−0.42
Weighted average shares	129,365	128M	127M	126M	124M	123M
Weighted average shares, diluted	129,365	133M	127M	126M	124M	123M

Balance sheet

Metric	31/03/2026	31/12/2025	30/09/2025	30/06/2025	31/03/2025	31/12/2024	30/09/2024	30/06/2024
Cash and equivalents	35M	43M	47M	73M	54M	72M	135M	85M
Receivables	144M	146M	115M

Cash flow

Metric	31/03/2026	31/03/2025
Operating cash flow	2M	−30M
Depreciation and amortisation	—	153,000
Share-based compensation	11M	10M
Capital expenditure	0	608,000
Investing cash flow	−11M	12M
Financing cash flow	1M

Amounts in USD unless stated otherwise. Data: US exchange trading and company filings with the regulator